BRPI0611674A2 - compostos quÍmicos - Google Patents

compostos quÍmicos

Info

Publication number: BRPI0611674A2
Authority: BR; Brazil
Prior art keywords: compound; directed; ikk2; compounds; activity
Prior art date: 2005-06-30

Application number

BRPI0611674-4A

Other languages

English (en)

Portuguese (pt)

Inventor

Jianghe Deng

Jeffrey K Kerns

Qi Jin

Guoliang Lin

Xichen Lin

Michael Lindenmuth

Christopher E Neipp

Hong Nie

Sonia M Thomas

Katherine L Widdowson

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-06-30

Filing date

2006-06-28

Publication date

2009-04-28

2006-06-28 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

2009-04-28 Publication of BRPI0611674A2 publication Critical patent/BRPI0611674A2/pt

Links

150000001875 compounds Chemical class 0.000 title abstract 7
102100021854 Inhibitor of nuclear factor kappa-B kinase subunit beta Human genes 0.000 abstract 3
101710205525 Inhibitor of nuclear factor kappa-B kinase subunit beta Proteins 0.000 abstract 3
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
208000035475 disorder Diseases 0.000 abstract 2
230000000694 effects Effects 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 2
VFHUJFBEFDVZPJ-UHFFFAOYSA-N 1h-indole-2-carboxamide Chemical class C1=CC=C2NC(C(=O)N)=CC2=C1 VFHUJFBEFDVZPJ-UHFFFAOYSA-N 0.000 abstract 1
101100508538 Homo sapiens IKBKE gene Proteins 0.000 abstract 1
102100021857 Inhibitor of nuclear factor kappa-B kinase subunit epsilon Human genes 0.000 abstract 1
208000006673 asthma Diseases 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Molecular Biology (AREA)

BRPI0611674-4A 2005-06-30 2006-06-28 compostos quÍmicos BRPI0611674A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US69525605P	2005-06-30	2005-06-30
PCT/US2006/025402 WO2007005534A2 (fr)	2005-06-30	2006-06-28	Composes chimiques

Publications (1)

Publication Number	Publication Date
BRPI0611674A2 true BRPI0611674A2 (pt)	2009-04-28

Family

ID=37605008

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0611674-4A BRPI0611674A2 (pt)	2005-06-30	2006-06-28	compostos quÍmicos

Country Status (19)

Country	Link
EP (1)	EP1896014A4 (fr)
JP (1)	JP5059756B2 (fr)
KR (1)	KR20080021077A (fr)
CN (1)	CN101247804B (fr)
AR (1)	AR055343A1 (fr)
AU (1)	AU2006266028B2 (fr)
BR (1)	BRPI0611674A2 (fr)
CA (1)	CA2613068A1 (fr)
EA (1)	EA014083B1 (fr)
IL (1)	IL187786A0 (fr)
MA (1)	MA29566B1 (fr)
MX (1)	MX2007016541A (fr)
NO (1)	NO20080457L (fr)
NZ (1)	NZ563687A (fr)
PE (1)	PE20070173A1 (fr)
TW (1)	TWI380973B (fr)
UA (1)	UA99699C2 (fr)
WO (1)	WO2007005534A2 (fr)
ZA (1)	ZA200709948B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0315950D0 (en)	2003-06-11	2003-08-13	Xention Discovery Ltd	Compounds
TW200626142A (en) *	2004-09-21	2006-08-01	Glaxo Group Ltd	Chemical compounds
GB0525164D0 (en) *	2005-12-09	2006-01-18	Xention Discovery Ltd	Compounds
US20080293802A1 (en) *	2005-12-16	2008-11-27	Smithline Beecham Corporation	Chemical Compounds
PE20081889A1 (es)	2007-03-23	2009-03-05	Smithkline Beecham Corp	Indol carboxamidas como inhibidores de ikk2
US8815840B2 (en) *	2008-12-19	2014-08-26	Bristol-Myers Squibb Company	Carbazole and carboline kinase inhibitors
WO2010102968A1 (fr) *	2009-03-10	2010-09-16	Glaxo Group Limited	Dérivés d'indole comme inhibiteurs de ikk2
JP6509838B2 (ja) *	2013-06-26	2019-05-08	アッヴィ・インコーポレイテッド	Ｂｔｋ阻害薬としての一級カルボキサミド類
EA034931B1 (ru) *	2014-10-24	2020-04-08	Бристол-Майерс Сквибб Компани	Индолкарбоксамидные соединения

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1272842A (zh) *	1997-08-06	2000-11-08	伊莱利利公司	作为速激肽受体拮抗剂的2－酰氨基丙胺类化合物
DE19807993A1 (de)	1998-02-26	1999-09-02	Bayer Ag	Verwendung von ß-Carbolinderivaten zur Bekämpfung von TNF-alpha-abhängigen Krankheiten
DE19928424A1 (de)	1999-06-23	2000-12-28	Aventis Pharma Gmbh	Substituierte Benzimidazole
SI1194425T1 (sl)	1999-06-23	2005-12-31	Sanofi Aventis Deutschland	Substituirani benzimidazoli
DE19951360A1 (de)	1999-10-26	2001-05-03	Aventis Pharma Gmbh	Substituierte Indole
GB0003154D0 (en)	2000-02-12	2000-04-05	Astrazeneca Uk Ltd	Novel compounds
WO2001068648A1 (fr)	2000-03-15	2001-09-20	Aventis Pharma Deutschland Gmbh	Beta-carbolines substituees ayant une activite inhibitrice de l'ikb-kinase
EP1209158A1 (fr)	2000-11-18	2002-05-29	Aventis Pharma Deutschland GmbH	Bêta-carbolines subtituées
EP1134221A1 (fr)	2000-03-15	2001-09-19	Aventis Pharma Deutschland GmbH	Bêta-carbolines substituées comme inhibiteurs de lkB kinase
JP2001278886A (ja) *	2000-03-28	2001-10-10	Dai Ichi Seiyaku Co Ltd	ベンゾオキサジン誘導体及びこれを含有する医薬
US6414013B1 (en)	2000-06-19	2002-07-02	Pharmacia & Upjohn S.P.A.	Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
JP4272338B2 (ja)	2000-09-22	2009-06-03	バイエルアクチェンゲゼルシャフト	ピリジン誘導体
AU2002211827B2 (en)	2000-10-03	2006-12-14	Bristol-Myers Squibb Company	Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
US6869956B2 (en)	2000-10-03	2005-03-22	Bristol-Myers Squibb Company	Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK)
WO2002030423A1 (fr)	2000-10-12	2002-04-18	Smithkline Beecham Corporation	Inhibiteurs du nf-$g(k)b
EP1324759A4 (fr)	2000-10-12	2004-05-12	Smithkline Beecham Corp	Inhibiteurs du nf-g(k)b
CA2427284A1 (fr)	2000-10-26	2002-05-30	Tularik Inc.	Agents anti-inflammatoires
JP2002193938A (ja)	2000-12-01	2002-07-10	Bayer Ag	４−アリールピリジン誘導体
US7122544B2 (en)	2000-12-06	2006-10-17	Signal Pharmaceuticals, Llc	Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
MXPA03006817A (es)	2001-02-01	2003-11-13	Bristol Myers Squibb Co	Metodo de tratamiento de enfermedades inflamatorias e inmunes usando inhibidores de la ikb cinasa (ikk).
WO2002094265A1 (fr)	2001-05-24	2002-11-28	Leo Pharma A/S	Procede de modulation de l'activite de nf-kb
US20030045515A1 (en)	2001-05-24	2003-03-06	Lise Binderup	Combination medicament for treatment of neoplastic diseases
IL158574A0 (en)	2001-05-24	2004-05-12	Leo Pharma As	Novel pyridyl cyanoguanidine compounds
US6638679B2 (en)	2001-07-12	2003-10-28	Kodak Polychrome Graphics, Llc	Photosensitive compositions having mixtures of alkoxy and non-alkoxy diazonium salt containing compounds
SE0102616D0 (sv)	2001-07-25	2001-07-25	Astrazeneca Ab	Novel compounds
SE0102617D0 (sv)	2001-07-25	2001-07-25	Astrazeneca Ab	Novel compounds
JP2005507892A (ja)	2001-09-19	2005-03-24	ファルマシア・コーポレーション	炎症の治療のための置換されたピラゾリルベンゼンスルファミド化合物
MXPA04002667A (es)	2001-09-19	2004-06-18	Pharmacia Corp	Compuestos de pirazolilo sustituido para el tratamiento de la inflacion.
BR0212613A (pt)	2001-09-19	2004-08-31	Pharmacia Corp	Compostos de indazol substituìdos para o tratamento de inflamação
ATE363473T1 (de)	2001-09-19	2007-06-15	Pharmacia Corp	Substituierte pyrazoloverbindungen zur behandlung von entzündungen
AU2002356871A1 (en)	2001-10-30	2003-05-12	Pharmacia Corporation	Heteroaromatic carboxamide derivatives for the treatment of inflammation
ES2291628T3 (es)	2002-04-03	2008-03-01	Bristol-Myers Squibb Company	Compuestos triciclicos a base de tiofeno y composiciones farmaceuticas que comprenden dichos compuestos.
EP1501805A1 (fr)	2002-05-09	2005-02-02	Pharmacia Corporation	Composes substitues de pyrazolyl utilises dans le traitement des inflammations
DK1513516T3 (da)	2002-06-06	2009-10-19	Boehringer Ingelheim Pharma	Substitueret 3-amino-thieno(2,3-b)-pyridin-2-carboxylsyreamid-forbindelser og fremgangsmåder til fremstilling og deres anvendelser
GB0217757D0 (en) *	2002-07-31	2002-09-11	Glaxo Group Ltd	Novel compounds
WO2004014851A2 (fr) *	2002-08-09	2004-02-19	Merck & Co., Inc.	Inhibiteurs de tyrosine kinases
DE10237722A1 (de)	2002-08-17	2004-08-19	Aventis Pharma Deutschland Gmbh	Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
WO2004075846A2 (fr)	2003-02-25	2004-09-10	Bristol-Myers Squibb Company	Composes tricycliques a base de pyrazolopurine et compositions pharmaceutiques renfermant ces composes
GB0308466D0 (en)	2003-04-11	2003-05-21	Novartis Ag	Organic compounds
US7176214B2 (en)	2003-05-21	2007-02-13	Bristol-Myers Squibb Company	Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
WO2005012283A1 (fr)	2003-07-31	2005-02-10	Boehringer Ingelheim Pharmaceuticals, Inc.	Composes de benzothiophene substitues et utilisations
US7265148B2 (en) *	2003-09-25	2007-09-04	Wyeth	Substituted pyrrole-indoles
US7291733B2 (en)	2003-10-10	2007-11-06	Boehringer Ingelheim Pharmaceuticals, Inc.	Substituted tricyclic heterocycles and their uses
WO2005035527A1 (fr)	2003-10-14	2005-04-21	Pharmacia Corporation	Composes de pyrazinone substitues pour le traitement de l'inflammation
GB0400895D0 (en) *	2004-01-15	2004-02-18	Smithkline Beecham Corp	Chemical compounds
AR050253A1 (es) *	2004-06-24	2006-10-11	Smithkline Beecham Corp	Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
TW200626142A (en) *	2004-09-21	2006-08-01	Glaxo Group Ltd	Chemical compounds
CN101060842A (zh) *	2004-09-21	2007-10-24	葛兰素集团有限公司	化合物

2006
- 2006-06-28 NZ NZ563687A patent/NZ563687A/en not_active IP Right Cessation
- 2006-06-28 AU AU2006266028A patent/AU2006266028B2/en not_active Ceased
- 2006-06-28 AR ARP060102790A patent/AR055343A1/es not_active Application Discontinuation
- 2006-06-28 UA UAA200714940A patent/UA99699C2/ru unknown
- 2006-06-28 CA CA002613068A patent/CA2613068A1/fr not_active Abandoned
- 2006-06-28 MX MX2007016541A patent/MX2007016541A/es active IP Right Grant
- 2006-06-28 EP EP06785861A patent/EP1896014A4/fr not_active Withdrawn
- 2006-06-28 BR BRPI0611674-4A patent/BRPI0611674A2/pt not_active IP Right Cessation
- 2006-06-28 WO PCT/US2006/025402 patent/WO2007005534A2/fr not_active Ceased
- 2006-06-28 CN CN2006800304481A patent/CN101247804B/zh not_active Expired - Fee Related
- 2006-06-28 TW TW095123240A patent/TWI380973B/zh not_active IP Right Cessation
- 2006-06-28 JP JP2008519569A patent/JP5059756B2/ja not_active Expired - Fee Related
- 2006-06-28 PE PE2006000761A patent/PE20070173A1/es not_active Application Discontinuation
- 2006-06-28 KR KR1020077030656A patent/KR20080021077A/ko not_active Ceased
- 2006-06-28 EA EA200800183A patent/EA014083B1/ru not_active IP Right Cessation
2007
- 2007-11-19 ZA ZA2007/09948A patent/ZA200709948B/en unknown
- 2007-11-29 IL IL187786A patent/IL187786A0/en unknown
- 2007-12-26 MA MA30513A patent/MA29566B1/fr unknown
2008
- 2008-01-24 NO NO20080457A patent/NO20080457L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
PE20070173A1 (es)	2007-03-14
EP1896014A2 (fr)	2008-03-12
CN101247804A (zh)	2008-08-20
CA2613068A1 (fr)	2007-01-11
KR20080021077A (ko)	2008-03-06
NZ563687A (en)	2011-07-29
MX2007016541A (es)	2008-03-07
AR055343A1 (es)	2007-08-22
TWI380973B (zh)	2013-01-01
AU2006266028A1 (en)	2007-01-11
JP5059756B2 (ja)	2012-10-31
CN101247804B (zh)	2012-09-26
WO2007005534A3 (fr)	2007-04-26
JP2009500338A (ja)	2009-01-08
NO20080457L (no)	2008-01-29
EA014083B1 (ru)	2010-08-30
ZA200709948B (en)	2009-03-25
AU2006266028B2 (en)	2012-03-15
EP1896014A4 (fr)	2010-07-21
IL187786A0 (en)	2008-08-07
EA200800183A1 (ru)	2008-08-29
UA99699C2 (ru)	2012-09-25
WO2007005534A2 (fr)	2007-01-11
MA29566B1 (fr)	2008-06-02
TW200738588A (en)	2007-10-16
WO2007005534A8 (fr)	2008-01-17

Legal Events

Date	Code	Title	Description
2008-11-18	B06G	Technical and formal requirements: other requirements [chapter 6.7 patent gazette]	Free format text: APRESENTE DOCUMENTO QUE ESCLARECA A DIVERGENCIA NO NOME DO PROCURADOR, UMA VEZ QUE AQUELE CONSTITUIDO NO ATO DO DEPOSITO NAO COINCIDE COM INDICADOS NO DOCUMENTO DE PROCURACAO E NO SUBSTABELECIMENTO.
2011-10-18	B25D	Requested change of name of applicant approved	Owner name: GLAXOSMITHKLINE LLC (US) Free format text: NOME ALTERADO DE: SMITHKLINE BEECHAM CORPORATION
2015-04-28	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 9A ANUIDADE.
2015-11-24	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2312 DE 28-04-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI0515524A (pt)	2008-07-29	compostos quìmicos
MX2009010270A (es)	2009-10-12	Indol carboxamidas como inhibidores de quinasas ikappa2.
BRPI0512533A (pt)	2008-03-25	carboxamidas indazol e seu uso
NO20084418L (no)	2008-12-23	Azolopyridin-3-on derivater som inhibitorer av endoteliallipase
ATE199544T1 (de)	2001-03-15	Substituierte indole als phosphodiesterase typ iv inhibitoren
TW200718424A (en)	2007-05-16	Novel compounds of amino sulfonyl derivatives
BRPI0407508A (pt)	2006-02-14	derivados de bifenila
TW200613306A (en)	2006-05-01	Imidazotriazines as protein kinase inhibitors
NO20063599L (no)	2006-10-27	Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
BRPI0817242A8 (pt)	2019-01-29	compostos derivados de 1,1,1-trifluoro-2-hidroxi-3-fenilpropano, processo para a sua manufatura e composições farmacêuticas que os contêm
BRPI0601282A (pt)	2007-05-08	composição, e método de modificar a formação de hidrato de gás
MY154895A (en)	2015-08-14	Pyrimidine hydrazide compounds as pgds inhibitors
NZ595196A (en)	2013-03-28	Peptide-based compounds for enzyme inhibition
TNSN08104A1 (en)	2009-07-14	Pyrimidine amide compounds as pgds inhibitors
EA201200423A1 (ru)	2012-08-30	Замещенные фенилуксусные кислоты как dp-2-антагонисты
MX2009011753A (es)	2009-12-01	Inhibidores de enzima de diacilglicerol o-aciltransferasa tipo 1.
MA28279A1 (fr)	2006-11-01	Derives d'indole et utilisation de ceux-ci comme inhibiteurs de kinase, notamment des inhibiteurs de ikk2
BRPI0611674A2 (pt)	2009-04-28	compostos quÍmicos
EA200801245A1 (ru)	2008-10-30	[4-(6-галоген-7-замещенные-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины и формы и способы, связанные с ними
NO20076448L (no)	2008-01-29	Novel piperidine carboxylic acid amide derivatives
WO2009055629A3 (fr)	2009-06-11	Antagonistes trpv1
WO2007076286A3 (fr)	2007-11-29	Composes chimiques
NO20064295L (no)	2006-09-22	Bruk av metylenamidderivater i kardiovaskulaere lidelser
DE602006010540D1 (de)	2009-12-31	(3,4-dihydro-chinazolin-2-yl)-(2-aryloxy-ethyl)-amine mit aktivität am 5-ht-rezeptor
BRPI0517955A (pt)	2008-10-21	indolizinas substituìdas e derivados como agentes de snc